About Genprex, Inc. Common Stock
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Market Cap
$0.00B
Employees
25
Listed Since
March 29, 2018
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.genprex.comPhone
512-537-7997
Headquarters
1601 TRINITY STREET, BLDG. B
AUSTIN, TX 78712
CIK
0001595248